COVID-19 vaccines
John and Jean Hutchinson, an elderly couple in their 80s, and Arthur Wilkinson, a 87-year-old pensioner, have shared their positive experiences with receiving the Covid-19 vaccination at special clinics in their area. The couple praised the NHS frontline staff for their efficiency and kindness, while Arthur described the experience as
Pharmaceutical industry
The global biosimilar therapeutic peptides market is expected to experience a significant decline in 2020 due to the COVID-19 pandemic, with sales dropping from $0.80 billion in 2019 to $0.77 billion in 2020 at a compound annual growth rate (CAGR) of -3.45%. However, the market is expected
COVID-19
As the European Union continues to tackle the COVID-19 pandemic, health policy spokesman Peter Liese from the European Parliament stressed the importance of securing sufficient vaccine supplies. The EU has secured 160 million doses of the mRNA-1273 vaccine from Moderna, a US-American manufacturer with production sites on the European continent.
Pharmaceutical industry
The Japanese Ministry of Health, Labor, and Welfare has granted concurrent approvals for the treatment of advanced ovarian, prostate, and pancreatic cancer with the use of LYNPARZA, a targeted therapy. The approvals are based on the results from the PAOLA-1, PROfound, and POLO Phase 3 trials, which demonstrated substantial progression-free
COVID-19
As the United Kingdom announced the approval of the Oxford/AstraZeneca vaccine, a massive drive to vaccinate millions of people got underway. The vaccine, developed by Oxford University and AstraZeneca, was approved by the Medicines and Healthcare Regulatory Agency (MHRA) on December 30, paving the way for a nationwide rollout
AstraZeneca PLC
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has authorized the emergency use of the Oxford-AstraZeneca COVID-19 vaccine, following rigorous clinical trials and a thorough analysis of the data. The vaccine has shown a 62% effectiveness in preventing COVID-19 among a group of 4,440 people, with
AstraZeneca PLC
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has authorized the use of the Oxford University-AstraZeneca COVID-19 vaccine, citing its safety, quality, and effectiveness. This vaccine joins the Pfizer/BioNTech vaccine already being administered in the country, with the National Health Service (NHS) prioritizing the rollout of
Pharmaceutical industry
The global immuno-oncology drugs market, which includes sales of immuno-oncology drugs used for the treatment of cancer and related services, is expected to decline in 2020 due to the COVID-19 pandemic. The market, which was valued at $59.64 billion in 2019, is expected to recover and reach $80.11
Pfizer Inc.
The arthritis monoclonal antibodies market is experiencing a decline in growth due to the COVID-19 pandemic, but it is expected to recover and reach $56.05 billion in 2023. The market was valued at $46.48 billion in 2019 and is expected to decline to $45.18 billion in 2020
Pharmaceutical industry
As the year comes to a close, Congress has reached an agreement on a Covid-19 relief bill, and stocks are enjoying a "Santa Rally" despite some sectors not faring well this past week. Politicians from both parties have received their first dose of the coronavirus vaccine, a potential
Pfizer Inc.
The Royal Bank of Canada's chief executive, Dave McKay, is cautioning that the country may still face economic challenges despite promising COVID-19 vaccine candidates. McKay warned that the economy could suffer due to the emergence of a second wave of the pandemic, projecting a decline in economic growth
Pharmaceutical industry
Selpercatinib, a novel and highly selective inhibitor of the RET protein, has shown promise in treating non-small cell lung cancer (NSCLC) patients, according to a study published in Future Oncology. Researchers at the Peter MacCallum Cancer Center conducted a Phase I/II clinical trial to evaluate the efficacy and safety
